Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-920 in Relapsed/Refractory NHL and MM
NCT07771361Phase 2Not yet recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
A Phase 2 trial of BAFF CAR-T in non-Hodgkin lymphoma (NHL), multiple myeloma (MM), sponsored by Luminary Therapeutics. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BAFF CAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07771361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771361.